About us: Big Arrow Group is an independent 9-year old, New York-based advertising agency that focuses on developing and supporting brands in regulated markets through traditional, digital and social marketing channels.
Our mission is to leverage rapidly evolving technologies to drive leadership and enhance the brand experience. We deliver unique, salient and positive brand strategies consistently and meaningfully across a range of diverse target audiences by integrating a multi-disciplinary approach from start to finish.
There’s a sense of intimacy with Big Arrow: We have no walls in our office and no walls with our clients. We commit to provide inclusive client experiences and a single-minded focus on our clients’ customers.
Key Staff: Michael Marino, President; Mike Teele, Business & Operations Director; Katherine Burton, Senior Account Director; Laura Higginson, Senior Account Director; Oksana Komarova, New Business Development
2012 Gross Income: $2-$5 Million
Full-time Employees: 10 (2012), 15 (2013), 28 (2014)
Current Healthcare accounts: Accenture; Aetna; Coordinated Health; CeQur, Ltd.; Genzyme: Cerezyme, Eliglustat, Fabrazyme, Myozyme; NYU Langone Medical Center: Harkness Center for Dance Injuries; Raptor Pharmaceuticals: PROCYSBI; Sigma Tau Pharmaceuticals: Abelcet, Proxeed, VSL#3; Wolters Kluwer
Services: Brand identity development, strategic planning, positioning/ messaging, unbranded disease education and awareness, campaign development, professional sales promotion, patient education materials, digital strategy and communications, and personalized targeted marketing
Featured Product: PROCYSBI (Raptor Pharmaceuticals)
Why this product is special: PROCYSBI is the first advancement in the management of nephropathic cystinosis in nearly two decades. Cystinosis is a rare, genetic disorder in which continuous cellular accumulation of the amino acid cystine rises to toxic levels, resulting in irreversible tissue and organ damage if left untreated even for a short time. Without treatment for cystinosis, life expectancy is 10 years or less, but with treatment patients may live into the 5th decade of life. PROCYSBI’s proprietary delayed-release technology allows for twice-daily dosing and full 12-hour coverage.